skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8102

Biologics: Targets and Therapy

(1,101,180) Views

Editor in Chief Dr Doris Mangiaracina Benbrook

1177-5475

Review
New advances in the treatment of adult chronic immune thrombocytopenic purpura: role of thrombopoietin receptor-stimulating agents
Ara Metjian, Charles S Abrams
Biologics: Targets and Therapy 2009, 3:499-513
04 December 2009

Review
Efficacy and safety of anakinra for the treatment of rheumatoid arthritis: an update of the Oregon Drug  Effectiveness Review Project
Kylie Thaler, Divya V Chandiramani, Richard A Hansen, et al
Biologics: Targets and Therapy 2009, 3:485-498
19 November 2009

Review
Targeted therapy in melanoma
Hussein Tawbi, Neelima Nimmagadda
Biologics: Targets and Therapy 2009, 3:475-484
16 October 2009

Original Research
Local cytokines and clinical symptoms in children with allergic rhinitis after different treatments
Gesmar RS Segundo, Fabíola A Gomes, Karla P Fernandes, et al
Biologics: Targets and Therapy 2009, 3:469-474
01 October 2009

Review
A systematic review of new advances in the management of mucopolysaccharidosis VI (Maroteaux-Lamy syndrome): focus on galsulfase
Regina P El Dib, Gregory M Pastores
Biologics: Targets and Therapy 2009, 3:459-468
28 September 2009

Review
Biological targets in the treatment of rheumatoid arthritis: a comprehensive review of current and in-development biological disease modifying anti-rheumatic drugs
Manil Kukar, Olga Petryna, Petros Efthimiou
Biologics: Targets and Therapy 2009, 3:443-457
28 September 2009

Review
Current use and potential role of bevacizumab in the treatment of gastrointestinal cancers
Jia Li, Muhammad Wasif Saif
Biologics: Targets and Therapy 2009, 3:429-441
07 September 2009

Review
Treatment of pancreatic cancer with epidermal growth factor receptor-targeted therapy
Bryan A Faller, Barbara Burtness
Biologics: Targets and Therapy 2009, 3:419-428
14 September 2009

Review
Review of the safety and efficacy of imiglucerase treatment of Gaucher disease
Deborah Elstein, Ari Zimran
Biologics: Targets and Therapy 2009, 3:407-417
31 August 2009

Review
Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies
Laith Altaweel, Daniel Sweeney, Xizhong Cui, et al
Biologics: Targets and Therapy 2009, 3:391-406
15 September 2009

Review
Safety and efficacy of pegylated liposomal doxorubicin in HIV-associated Kaposi’s sarcoma
Francesca Cainelli, Alfredo Vallone
Biologics: Targets and Therapy 2009, 3:385-390
17 August 2009

Review
Finding a new drug and vaccine for emerging swine flu: What is the concept?
Viroj Wiwanitkit
Biologics: Targets and Therapy 2009, 3:377-383
05 August 2009

Review
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
Damiano Paolicelli, Vita Direnzo, Maria Trojano
Biologics: Targets and Therapy 2009, 3:369-376
13 July 2009

Review
First-line treatment of acute lymphoblastic leukemia with pegasparaginase
Riccardo Masetti, Andrea Pession
Biologics: Targets and Therapy 2009, 3:359-368
07 July 2009

Review
Pegademase bovine (PEG-ADA) for the treatment of infants and children with severe combined immunodeficiency (SCID
Claire Booth, H Bobby Gaspar
Biologics: Targets and Therapy 2009, 3:349-358
24 June 2009

Review
Lutropin alpha, recombinant human luteinizing hormone, for the stimulation of follicular development in profoundly LH-deficient hypogonadotropic hypogonadal women: a review

Bernd Th Krause, Ralf Ohlinger, Annette Haase


Biologics: Targets and Therapy 2009, 3:337-347
26 June 2009

Review
Anti-interleukin-2 receptor antibodies—basiliximab and daclizumab—for the prevention of acute rejection in renal transplantation
Junichiro Sageshima, Gaetano Ciancio, Linda Chen, George W Burke III
Biologics: Targets and Therapy 2009, 3:319-336
17 June 2009

Review
Targeted treatment of psoriasis with adalimumab: a critical appraisal based on a systematic review of the literature
Jochen Schmitt, Gottfried Wozel
Biologics: Targets and Therapy 2009, 3:303-318
11 June 2009

Review
HER2 breast cancer therapies: a review
Conleth G Murphy, Shanu Modi
Biologics: Targets and Therapy 2009, 3:289-301
11 June 2009

Review
The old and new therapeutic approaches to the treatment of giardiasis: Where are we?
Haendel GNO Busatti, Joseph FG Santos, Maria A Gomes
Biologics: Targets and Therapy 2009, 3:273-287
05 June 2009

Review
Early stage and long term treatment of multiple sclerosis with interferon-β
Angela Applebee, Hillel Panitch
Biologics: Targets and Therapy 2009, 3:257-271
28 May 2009

Review
Methods, potentials, and limitations of gene delivery to regenerate central nervous system cells
Arvind Kumar, Tryambak D Singh, Santosh K Singh, Satya Prakash
Biologics: Targets and Therapy 2009, 3:245-256
15 May 2009

Review
Potentials and limitations of microorganisms as renal failure biotherapeutics
Poonam Jain, Sapna Shah, Razek Coussa, Satya Prakash
Biologics: Targets and Therapy 2009, 3:233-243
18 May 2009

Review
B cell reductive therapy with rituximab in the treatment of rheumatoid arthritis
Joseph M Tuscano, Jacob Sands
Biologics: Targets and Therapy 2009, 3:225-232
13 May 2009

Review
EGFR targeted therapy in non-small cell lung cancer: potential role of cetuximab
Chad A Reade, Apar Kishor Ganti
Biologics: Targets and Therapy 2009, 3:215-224
11 May 2009

Review
Dasatinib in the treatment of imatinib refractory chronic myeloid leukemia
Radhakrishnan Ramchandren, Charles A Schiffer
Biologics: Targets and Therapy 2009, 3:205-214
08 May 2009

Review
Safety and efficacy of alpha-1-antitrypsin augmentation therapy in the treatment of patients with alpha-1-antitrypsin deficiency
Irina Petrache, Joud Hajjar, Michael Campos
Biologics: Targets and Therapy 2009, 3:193-204
04 May 2009

Review
Infliximab in the treatment of rheumatoid arthritis
A Perdriger
Biologics: Targets and Therapy 2009, 3:183-191
07 May 2009

Review
Long-term pegylated interferon-α and its potential in the treatment of melanoma
Reinhard Dummer, Joanna Mangana
Biologics: Targets and Therapy 2009, 3:169-182
17 April 2009

Review
Ustekinumab in the therapy of chronic plaque psoriasis
Jenna L O’Neill, Robert E Kalb
Biologics: Targets and Therapy 2009, 3:159-168
25 March 2009

Review
Treatment of immune thrombocytopenic purpura: focus on eltrombopag
Lawrence Rice
Biologics: Targets and Therapy 2009, 3:151-157
19 March 2009

Review
Management of chronic hepatitis C treatment failures: role of consensus interferon
Stevan A Gonzalez, Emmet B Keeffe
Biologics: Targets and Therapy 2009, 3:141-150
18 March 2009

Review
Challenges in the management of juvenile idiopathic arthritis with etanercept
Clare E Pain, Liza J McCann
Biologics: Targets and Therapy 2009, 3:127-139
16 March 2009

Review
Antihemophilic factor (recombinant) plasma/albumin-free method for the management and prevention of bleeding episodes in patients with hemophilia A
Steven Pipe
Biologics: Targets and Therapy 2009, 3:117-125
16 February 2009

Review
Palifermin for management of treatment-induced oral mucositis in cancer patients
Andrei Barasch, Joel Epstein, Ken Tilashalski
Biologics: Targets and Therapy 2009, 3:111-116
16 February 2009

Review
Front line treatment of elderly multiple myeloma in the era of novel agents
Marie-Dominique Venon, Aldo M Roccaro, Julie Gay, Anne-Sophie Moreau, Remy Dulery, et al
Biologics: Targets and Therapy 2009, 3:99-109
30 October 2008

Review
Biologic targeting in the treatment of inflammatory bowel diseases
Matteo Bosani, Sandro Ardizzone, Gabriele Bianchi Porro
Biologics: Targets and Therapy 2009, 3:77-97
09 February 2009

Review
Gene targeted therapeutics for liver disease in alpha-1 antitrypsin deficiency
Caitriona McLean, Catherine M Greene, Noel G McElvaney
Biologics: Targets and Therapy 2009, 3:63-75
21 January 2009

Review
Anti-RhD immunoglobulin in the treatment of immune thrombocytopenia
Eric Cheung, Howard A Liebman
Biologics: Targets and Therapy 2009, 3:57-62
08 January 2009

Original Research
Basiliximab induction therapy in kidney transplantation: Benefits for long term allograft function after 10 years?
Martina Koch, Thomas Becker, Rainer Lueck, Michael Neipp, Juergen Klempnauer, Bjoern Nashan
Biologics: Targets and Therapy 2009, 3:51-56
12 January 2009

Review
Maintenance treatment with infliximab for the management of Crohn’s disease in adults
Renato Caviglia, Ivo Boškoski, Michele Cicala
Biologics: Targets and Therapy 2009, 3:39-49
05 January 2009

Original Research
Effectiveness of cytopenia prophylaxis for different filgrastim and pegfilgrastim schedules in a chemotherapy mouse model
Markus Scholz, Manuela Ackermann, Frank Emmrich, Markus Loeffler, Manja Kamprad
Biologics: Targets and Therapy 2009, 3:27-37
17 December 2008

Review
Current available therapies and future directions in the treatment of malignant gliomas
Annick Desjardins, David A Reardon, James J Vredenburgh
Biologics: Targets and Therapy 2009, 3:15-25
17 December 2008

Review
Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer
Bernadette Biondi, Melania Pulcrano, Loredana Pagano, Gaetano Lombardi
Biologics: Targets and Therapy 2009, 3:9-13
02 December 2008

Review
Botulinum toxin type A in the treatment of patients with cervical dystonia
Allison Brashear
Biologics: Targets and Therapy 2009, 3:1-7
01 December 2008

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University

  • Journal Indexing

    See where all the Dove Press journals are indexed